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Abstract: Diabetes Mellitus (DM) and Alzheimer's disease (AD) are two prevalent diseases in 
modern societies, which are caused mainly by current lifestyle, aging and genetic alterations. It has 
already been demonstrated that these two diseases are associated, since individuals suffering from 
DM are prone to develop AD. Conversely, it is also known that individuals with AD are more sus-
ceptible to DM, namely type 2 diabetes (T2DM). Therefore, these two pathologies, although com-
pletely different in terms of symptomatology, end up sharing several mechanisms at the molecular 
level, with the most obvious being the increase of oxidative stress and inflammation. 
Polyphenols are natural compounds widely spread in fruits and vegetables whose dietary intake has 
been considered inversely proportional to the incidence of DM and AD. So, it is believed that this 
group of phytochemicals may have preventive and therapeutic potential, not only by reducing the 
risk and delaying the development of these pathologies, but also by improving brain’s metabolic 
profile and cognitive function. 
The aim of this review is to understand the extent to which DM and AD are related pathologies, the 
degree of similarity and the relationship between them, to detail the molecular mechanisms by 
which polyphenols may exert a protective effect, such as antioxidant and anti-inflammatory effects, 
and highlight possible advantages of their use as common preventive and therapeutic alternatives. 
Keywords: Polyphenols, diabetes mellitus, alzheimer's disease, diabetes mellitus and alzheimer's disease link, antidiabetic 
therapy, neuroprotection. 
1. INTRODUCTION 
 Lifestyle changes and increased longevity of the popula-
tion have made more prone the emergence of diseases trig-
gered by imbalanced diets and aging, as is the case of Diabe-
tes Mellitus (DM) and Alzheimer’s disease (AD) [1, 2]. DM 
is one of the most prevalent chronic metabolic diseases in 
developed countries [3]. Globally, the prevalence of DM has 
doubled, as the number of adults suffering from DM reached 
425 million in 2017 [1], compared to 171 million at the be-
ginning of the 21st century [3]. According to recent projec-
tions, this number will continue to rise, and it is expected 
that by 2045 about 629 million adults will suffer from DM 
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[1]. Alarmingly, there is also a noticeable increasing trend of 
DM onset among children and adolescents [4]. Meanwhile, 
AD is the most common neurodegenerative disease world-
wide, leading to 60-70% of all cases of dementia [5, 6]. In 
2016, nearly 50 million people had AD and it is predicted 
that by 2050 the number of people affected will be more than 
131 million, as the number is expected to double every 20 
years [7]. Therefore, DM and AD are a rising trend, affecting 
more people each year, and present the risk of becoming the 
major public health problems of the near future, contributing 
to higher morbidity, disability and mortality [3, 8]. Although 
the projected increase in DM and AD cases is derived from 
population growth and aging, the main cause can also be 
attributed to an increase in risk factors for these diseases [1, 
7]. DM and AD are multifactorial diseases that result from a 
combination of genetic, epigenetic and lifestyle risk factors 
[9, 10]. As such, common risk factors for these pathologies 
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cal inactivity, metabolic diseases and smoking [1, 4, 7, 9]. 
Therefore, a healthy lifestyle is fundamental to reduce risk 
factors and prevent the development of DM and AD [4, 11]. 
 Interestingly, a study by Liebson et al. [12] suggested 
that DM increased the risk of an individual developing AD. 
In fact, patients with DM often experience a sharp decline in 
cognitive function [13, 14]. Despite this, it is not only DM 
that contributes to AD, as it is known that a large percentage 
of patients with AD present altered blood glucose levels, 
which makes them more likely to develop DM [15]. Several 
studies have evidenced that these diseases are intertwined 
[13, 14, 16, 17], and therefore, it is important to understand 
how they are associated and find solutions to combat these 
two pathologies. However, this is a subject of some contro-
versy [18]. In this context, many studies have been con-
ducted to search for drugs capable of curbing these diseases 
[19-23] and to search for therapeutic alternatives more af-
fordable and accessible to the population [24-26]. Among 
DM and AD risk factors, diet is the most easily modifiable 
[4, 25], which led to an increasing search of nutraceuticals 
and other natural compounds able not only of protecting 
against these pathologies, but also able to curb some of its 
main symptoms [24-27]. 
 In recent years, the number of studies related to phenolic 
compounds has rapidly increased. This growing interest is 
related to the recognition of polyphenols as abundant com-
ponents of our diet showing antioxidant properties. It has 
been demonstrated that polyphenols play a beneficial role in 
various diseases such as cancer, cardiovascular diseases, 
DM, neurodegenerative diseases and many others. However, 
polyphenols as bioactive substances present in various foods, 
including a large variety of fruits, nuts, spices, vegetables 
and herbal infusions, are now the object of study of several 
researches, not only for their antioxidant properties, but also 
for the involvement in several other cellular and enzymatic 
mechanisms where they are believed to have an important 
role [28]. For that reason, several studies have emerged illus-
trating that polyphenols are potential multifunctional agents 
capable of delaying the onset or the progression of these pa-
thologies. [27, 29-31]. 
 This review aims to show the association between DM 
and AD and to find therapeutic alternatives to prevent and 
treat both diseases through nutraceuticals consumption, as is 
the case of polyphenols. Extensively recognized beneficial 
phenolic compounds and representatives of the most impor-
tant classes/subclasses, namely catechins, resveratrol and 
curcumin, as well as others that have been more recently 
studied, specifically luteolin, quercetin, genistein and gallic 
acid, are discussed in this review to give a broad perspective 
of the subject and present new advances in the field. Thus, 
throughout this article, it will be discussed how polyphenols 
contribute to antidiabetic and neural protection factors. 
2. DIABETES MELLITUS AND ALZHEIMER’S 
DISEASE: TWO DIFFERENT PATHOLOGIES 
SHARING CHARACTERISTICS 
2.1. Diabetes Mellitus 
 DM is a metabolic disease that results from a failure in 
the secretion and/or action of insulin. This hormone is pro-
duced in pancreatic β-cells and allows cells to capture glu-
cose to meet energy needs [32]. When insulin is absent or 
when its function is abnormal, cells are not able to take up 
glucose, thus it remains in the bloodstream causing hyper-
glycaemia [33]. In healthy individuals, glycaemia is tightly 
regulated, and fasting plasma glucose is maintained between 
3.9–5.6 mmol/L, while postmeal exceeds this range only up 
to 3 mmol/L [34]. During the development of DM, the con-
trol of blood glucose levels becomes abnormal. In fact, stud-
ies have supported the idea that at the prodromal stages of 
DM, pancreatic β-cells may become dysfunctional, so that 
insulin resistance occurs before the establishment of DM. In 
addition, hyperglycaemia decreases the expression of 5' 
adenosine monophosphate-activated protein kinase (AMPK), 
and, consequently, the expression of sirtuin 1 (SIRT1), a 
nicotinamide adenine dinucleotide (NAD)-dependent deace-
tylase member of the silent information regulator 2 family 
[35, 36]. In fact, SIRT1 was found to suffer a marked level 
and activity decrease in the liver and pancreas of rats follow-
ing induction of DM [35]. AMPK and SIRT1 have a recipro-
cal activation dynamic in which AMPK activates SIRT1, via 
increasing its substrate NAD [37], while SIRT1 deacetylates 
and thus activates AMPK [38]. AMPK prevents the produc-
tion of glucose, cholesterol and triglycerides promoting the 
oxidation of fatty acids. On the other hand, SIRT1 is respon-
sible for regulating hepatic glucose production, lipid metabo-
lism and stimulate insulin production and its sensitivity, 
being an important regulator of energy metabolism [36]. 
Accordingly, transgenic mice that overexpress SIRT1 dis-
play improved glucose homeostasis and increased metabolic 
rates [39]. Moreover, SIRT1, through deacetylation also 
regulates the activity of peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PGC-1α) responsible 
for suppressing reactive oxygen species (ROS) production 
and regulator of mitochondrial biogenesis [40]. Thus, AMPK 
and SIRT1 decrease with DM, leaves no impediment to the 
production of glucose and ROS [36]. 
 The majority of DM cases are classified as type 1 DM 
(T1DM) or type 2 DM (T2DM). T1DM is characterized by 
an autoimmune response of T lymphocytes to insulin-
producing β-cells [41]. The loss of pancreatic β-cells is pro-
gressive and results in a dramatic decrease or even in the 
absence of insulin production. As consequence, these indi-
viduals are dependent on exogenous administration of insu-
lin to survive. The first symptoms of T1DM generally appear 
in the early years, and this is why it is known as juvenile-
onset DM. Uncontrolled T1DM can lead to ketoacidosis, 
which can be lethal [32, 33]. Following the trend of DM, the 
number of T1DM individuals has also been considerably 
increasing. It is expected that the prevalence of T1DM in 
individuals younger than 5 years will double until 2020 [42]. 
Studies indicate that the causes for this self-destruction are 
genetic, but it is also believed that environmental factors are 
increasingly contributing to the rise of these numbers [32, 33]. 
 In turn, T2DM accounts for almost 95% of diabetics and 
is also known as non-insulin dependent DM. It usually tends 
to appear at advanced ages and in the early stages, a decrease 
in the sensitivity to insulin is observed [32]. This is called 
insulin resistance, and to compensate this state, pancreatic β-
cells increase the rate of insulin secretion leading to a hyper-
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insulinemia. However, with the progression of T2DM, β-
pancreatic cells lose the capacity to release adequate 
amounts of insulin to compensate the resistance to the hor-
mone and individuals develop a more or less severe insulin 
deficiency. The risk of developing T2DM has a genetic pre-
disposition, but the major risk factors are increased age, obe-
sity and lack of physical exercise [32, 33]. 
 DM is characterized by significant metabolic alterations 
which are associated with the development of several com-
plications, such as cardiovascular problems, foot ulcers, sex-
ual dysfunction, retinopathy, nephropathy and neurodegen-
erative diseases [32, 33, 43]. However, depending on the 
severity degree of DM, polyuria, polydipsia [32], polyphagia 
[32, 33], weight loss, blurred vision [32], the difficulty of 
healing [33] and a greater vulnerability to infections [32] 
also occur. DM is associated with several complications in 
different organs. For instance, the resulting hyperglycaemia 
may compromise lung function contributing to the weakness 
of muscles involved in respiration and decreased gas ex-
change at the level of the alveoli. Nandhini et al. [44] 
showed that the resistance and efficiency of the ventilatory 
pump are affected by myopathic and neuropathic changes 
that in turn affect the respiratory muscles. This is consistent 
with Davis et al. [45] who found that diabetic individuals 
had a reduced air flow when compared to healthy controls. It 
is also true that DM is associated with high levels of in-
flammatory mediators and markers, that in conjunction with 
microangiopathy, cause changes in lung matrix proteins, 
compromising lung functions. DM may induce microan-
giopathic changes in the lung causing an increase in the 
thickness of the basal lamina that ends-up compromising the 
gas exchange [46]. It is possible that alterations in the colla-
gen metabolism may impact the capacity of the chest to ex-
pand correctly, resulting in significantly lower lung volumes 
[47]. 
 The efforts to find a cure to DM have greatly increased 
over the years, with several studies done on this matter, but 
the standard form of treatment continues to be through die-
tary and lifestyle modifications and drug therapy with hypo-
glycaemics, such as sulphonylureas, α-glucosidase inhibitors 
and thiazolidenediones. When blood glucose levels cannot 
be controlled in this way there is a need to administer exoge-
nous insulin, which is typically the case of T1DM. However, 
a healthy diet is fundamental to control DM pathogenesis, as 
it can help to delay the complications associated with DM or 
even prevent DM development [48]. 
2.2. Alzheimer’s Disease 
 The AD is the most frequent neurodegenerative disorder 
in the elderly. It is characterized by loss of memory and 
damage to problem-solving ability, spatial skills, language, 
or socio-affective behaviour. The clinical diagnosis of this 
disease requires that the individual presents symptoms in at 
least two of these cognitive domains [49]. However, depend-
ing on the stage of the disease, depression, anxiety, apathy 
and irritability may also be present, while in more severe 
states individuals show agitation, aggressive behaviour and 
even hallucinations [50]. AD is a multifactorial disease, 
caused by both genetic and environmental factors. A small 
number of cases are caused by autosomal dominant trans-
mission involving genes encoding amyloid precursor protein 
(APP), presenilin 1 (PS1) and presenilin 2 (PS2) [51]. AD 
presents three stages: an initial phase, an intermediate phase 
and a late stage. In the first phase, the cholinergic neurons 
located in the hippocampus are affected and cause losses of 
less significant memories. The intermediate phase may pro-
long for ten years and is characterized by a decrease in the 
levels of acetylcholine (ACh) in the neurons responsible for 
the storage of long-term memories [52]. During this phase, 
other symptoms, such as personality changes, confusion, 
anger and lack of orientation begin to appear. ACh is known 
to play an important role in memory and learning [53]. ACh 
is synthesized by choline acetyltransferase and hydrolysed 
by cholinesterase. There are two isoforms of cholinesterase, 
acetylcholinesterase (AChE) that is very selective for ACh 
hydrolysis, and butyrylcholinesterase (BChE) that is able to 
metabolize other molecules [54, 55]. Evidence has indicated 
that in more advanced stages of AD, AChE levels decrease 
by about 85%, while BChE levels increase twice and become 
the main cholinesterase in the brain. As a consequence, the 
hydrolysis of ACh will become less selective and its concen-
tration in the brain begins to decrease leading to memory 
loss [54]. However, it is also believed that mitochondria play 
crucial roles [56, 57]. Mitochondrial function tends to de-
crease with age [58] and has been described as dysfunctional 
in brains of rats with AD. Dysfunctional mitochondria pre-
sent defects in the correct function of electron transport 
chain, which eventually leads to the production of ROS, 
which in turn leads to the oxidation of thioredoxin that 
causes dissociation of signal regulating kinase 1 apoptosis. 
This interaction results in the activation of c-Jun N-terminal 
kinases that will increase the expression of β-secretase 1 and 
PS1, two genes that contribute to the fragmentation of APP, 
which results in increased production of β-amyloid peptide 
[59-61]. In the last phase of AD, the cholinergic neurons of 
the cerebral cortex are affected and stored memories are lost, 
the patient forgets about his/her past and sometimes even 
his/her family. This phase is less durable, although it can last 
for three years, and ends with death [62]. 
 AD is associated with loss of activity in specific brain 
regions, mainly in the temporal and parietal lobes [63]. The 
causes are plaques composed of insoluble β-amyloid pep-
tides and neurofibrillary tangles (NFT), composed of hyper-
phosphorylated tau proteins [5]. These proteins initially have 
the function of stabilizing the microtubules of the neurons 
but, when they are hyperphosphorylated, they lose affinity to 
the tubulins that constitute these microtubules and aggregate 
to each other, leading to the formation of the NFT [64]. β-
amyloid plaques and NFT begin to be present in brain-bound 
areas of memory and learning where loss of neurons and 
synapses occurs, and subsequently spread throughout all 
areas of the brain resulting in the different stages of the dis-
ease [5]. The reason for this is unclear, but the main hy-
potheses have addressed n the modification of β-amyloid 
peptides. These are comprised of 38 to 43 amino acids and 
their formation results from the proteolytic process of APP. 
When APP is normally processed by α-secretase and subse-
quently by γ-secretase, a compound is formed which is rap-
idly degraded in the body. However, due to mutations, oxi-
dative stress and aging, APP can be processed by β- and γ-
secretase and generate β-amyloid peptides [5]. Because of 
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this imbalance, the β-amyloid peptides aggregate into soluble 
oligomers, which merge, giving origin to unsolvable β-
amyloid plaques that are to be deposited in the various brain 
lobes. The β-amyloid plaques in conjunction with NFT can 
trigger an inflammatory process by activating astrocytes and 
microglia that lead to increased mobilization of macrophages 
and lymphocytes, which in turn will release tumour necrosis 
alpha factor (TNF-α) and interferon gamma. These cytokines 
increase the levels of β-secretase 1 and APP in astrocytes 
and microglia contributing to the formation of β-amyloid 
peptides in these cells causing brain damage [65-68]. 
 It has been noted that SIRT1 is down-regulated in the 
parietal cortex of AD patients and this loss is correlated with 
AD progression [69]. Studies show that SIRT1 is capable of 
promoting α-secretase activity in different models, conse-
quently reducing the production of β-amyloid peptides [70]. 
Also, SIRT1 deacetylates p53 and forkhead box O (FOXO) 
proteins, leading to the suppression of their apoptotic activity 
in neurons and hence promoting neuronal survival [71]. 
Therefore, SIRT1 loss in AD might promote the accumula-
tion of β-amyloid peptides, consequently originating more β-
amyloid plaques, and lead to apoptotic death of neurons. 
Furthermore, SIRT1 activity reduction has been shown to 
limit AD brain capacity of generating acetyl-coenzyme A, a 
precursor of ACh [72], and relates to decreased mitochon-
drial biogenesis, which contributes to mitochondrial dys-
function [73]. 
 On the other hand, other authors have argued that β-
amyloid plaques also alter the permeability of Ca2+ channels 
in glia cells, leading to the formation of Fe2+ and Cu2+ ions 
and, consequently, ROS production [74]. Studies have 
shown that β-amyloid produces hydrogen peroxide and re-
leases substances reactive to thiobarbituric acid. In addition, 
they induce neurodegeneration through microglial nicotina-
mide adenine dinucleotide phosphate (NADPH) oxidase, 
though this mechanism is not entirely understood [75]. The 
characteristic oxidative stress of AD will affect oligodendro-
cytes, as they remain with a low concentration of reduced 
glutathione (GSH) and a high concentration of iron, render-
ing the cells incapable of eliminating oxygen radicals [74]. 
 Nonetheless, the formation of β-amyloid aggregates can 
also be triggered by genetic mutations. Mutations in the APP 
gene may occur in familial forms of AD with early onset 
(about 40 years of age). The main cause of early-onset famil-
ial AD forms is the mutations in the presenilin 1 gene 
(PSEN1) and presenilin 2 (PSEN2) gene. However, muta-
tions in PSEN1, the gene that encodes for PS1, the core pro-
tein of the catalytic subunit of the γ-secretase complex, cause 
the majority and the most severe forms of the disease. In 
fact, so far, 219 mutations have been reported in the PSEN1 
gene, with the majority being missense mutations and the 
most common being mutation E280 [76]. Very early onset 
AD (mean age of 30 years) has also been associated with the 
pathogenic variants p.Met233Val and p.Tyr256Ser PSEN1 
[77]. In turn, late onset is due to the apolipoprotein E (ApoE) 
gene encoding the ApoE protein, involved in the metabolism 
of fatty acids. This gene has the APOε2, APOε3 and APOε4 
alleles, the latter being a major genetic risk factor for AD 
[78]. Although it is not yet known the reason why this allele 
increases the odds of developing AD, it is known that, when 
present in heterozygosity, the genetic risk is 3-fold increased, 
whereas in homozygosity, the risk is 10-fold increased [56]. 
Interestingly, APOε4, contrary to other alleles, has been 
linked with SIRT1 expression reduction, leading to reduced 
neuroprotection [79]. 
 Due to the complexity of AD, and although there is still 
no cure, there are several targets for the therapeutic effects of 
drugs. The currently available treatments delay ACh degra-
dation, interfere with APP metabolism, and inhibit tau phos-
phorylation [74]. 
2.3. The Link between Diabetes Mellitus and Alzheimer’s 
Disease 
 DM and AD are two diseases that are very prevalent in 
modern societies contributing to a great decrease in the qual-
ity of life. The association between these two diseases is an 
issue of increasing interest and particular concern for health 
authorities [80]. Both DM and AD share several common 
risk factors and developing pathways, which is not surprising 
once oxidative stress, inflammation and alteration of energy 
homeostasis appear to be the key mechanisms in both pa-
thologies. Furthermore, one of the main risk factors for the 
development of DM and AD is aging, which is by itself as-
sociated with the increase of the mechanisms mentioned 
above, as well as with epigenetic changes, the most notewor-
thy being the decrease in the expression of SIRT1 [81, 82], 
the histone deacetylase believed to be directly related to 
regulation of adipogenesis and adipolysis, mitochondrial 
biogenesis, suppression of β-amyloid production and neuro-
protection, therefore the decrease of its expression is preju-
dicial for both metabolic and neurodegenerative diseases 
[83-85]. Besides SIRT1 down-regulation with aging, this 
deacetylase was also found to be down-regulated in DM [35] 
and AD [69] models, which further supports its involvement 
in both pathologies. 
 Leibson et al. [12] suggested that DM increased the risk 
of AD development by 2.27-fold in males and 1.37-fold in 
females, and that individuals who were being treated with 
insulin had a 4.3-fold greater risk of developing AD than 
healthy individuals. In some studies, higher insulin and glu-
cose levels have been detected in AD individuals compared 
with healthy people [86, 87]. These findings have led to con-
sider that insulin dysfunction, or the resulting hyperglycae-
mic state, increases the risk for the development of AD (Fig. 
1) [86, 87]. Another line of thought emerged later, arguing 
that it is the insulin deficiency that causes AD since insulin 
cannot perform its function in the brain [88, 89] and thus 
undermines the process of learning and memory retention 
[90]. The majority of the insulin present in the brain is pro-
duced by the β-pancreatic cells and crosses the blood-brain 
barrier. It acts at the level of the hypothalamus, controls the 
need for food intake and acts on cognitive functions. Its ac-
tion begins when it binds to the insulin receptor, therefore 
activating tyrosine kinase phosphorylation which in turn 
stimulates other neuronal pathways [91]. Activation of the 
Sarcoma homology collagen mitogen-activated protein 
pathway leads to the development of neuronal cell growth and 
repair processes [92]. Besides this, insulin also induces the 
production of nitric oxide, essential in learning and memory 
processes. Thus, problems related to insulin production, 
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Fig. (1). Schematic representation of overlapping molecular mechanisms involved in the onset and progression of DM and AD that can be 
modulated by the specific action of phenolic compounds. Decreasing levels of insulin (and/or insulin action), a characteristic of DM, contrib-
ute to the decrease in IGF that causes a decrease in acetyl-CoA levels which, consequently, causes a decrease in ACh levels, leading to cogni-
tive decline. In addition, the high levels of ROS (increased due to the dysregulation of glucose metabolism caused by decreased insulin levels 
and/or insulin action) activate the caspase-dependent pathway that results in cellular apoptosis and, consequently, destroys nerve cells. ROS 
also oxidize thioredoxin, which increases the expression of the BACE1 and PS1, genes responsible for β-amyloid peptide production. Con-
vergently, the production of this peptide is also enhanced by the release of inflammatory cytokines, such as IL-1, IL-6 and TNF-α, promoted 
by ROS. Increased β-amyloid peptide production is characteristic of AD and inhibits autophosphorylation of insulin receptors, contributing to 
increased insulin resistance (characteristic of DM), and therefore, to hyperglycaemia. Phenolic compounds can act in some of the mechanisms 
previously described, having a positive effect in DM and AD. For instance, EGCG is able to increase insulin secretion, and thus, ameliorate 
hyperglycaemia. Catechins (namely EC, ECG, EGC and EGCG), theaflavins and quercetin can delay or inhibit the hydrolysis of ACh, pre-
venting the decrease of ACh levels. Several phenolic compounds, such as genistein, resveratrol, EC, EGC, EGCG, gallic acid, luteolin, cur-
cumin and quercetin can act as antioxidants, reducing ROS levels, and therefore reducing the activation of mechanisms of pathogenesis pro-
gression. Furthermore, genistein, resveratrol, EGCG and gallic acid are capable of modulating caspase 3, while luteolin can down-regulate 
PS1 expression, and resveratrol, curcumin and luteolin can decrease inflammatory cytokines release, and so, these compounds can have an 
inhibiting effect on apoptosis and/or β-amyloid peptide formation besides through ROS modulation. Upwards arrows and downwards arrows 
(grey) represent increase and decrease, respectively. Arrow-headed lines and bar-headed lines (black) represent activation and inhibition, 
respectively. The ball-headed lines (grey) represent the effect of the phenolic compounds. Acetyl-CoA - Acetyl-coenzyme A; ACh - 
Acetylcholine; Apaf-9 - Apoptotic protease activating factor 1; BACE1 - β-secretase 1; EC - Epicatechin; ECG - Epicatechin gallate; EGC - 
Epigallocatechin; EGCG - Epigallocatechin-3-gallate; IGF - Insulin-like growth factor; IL-1 - Interleukin 1; IL-6 - Interleukin 6; JNK - c-Jun 
N-terminal kinases; NF-kB - Nuclear factor kappa-light-chain-enhancer of activated B cells; PS1 - Presenilin 1; ROS - Reactive oxygen spe-
cies; TNF-α - Tumour Necrosis Factor alpha; Trx – Thioredoxin. 
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action or resistance are at the origin of complications at the 
level of the central nervous system, including AD [93]. 
Other evidence that DM and AD are related is the decrease 
in levels of ACh caused by insulin depletion or resistance. 
The process of formation of ACh, an important neurotrans-
mitter for control of memory-related brain areas, involves 
acetyl-coenzyme A and acetyl transferase. When the level of 
insulin is decreased, the expression of the insulin-like growth 
factor I (IGF-I), which stimulates the energy metabolism 
necessary for the formation of acetyl-coenzyme A, also de-
creases. Furthermore, as previously stated, SIRT1 down-
regulation, which is verified both in DM and AD, also limits 
acetyl-coenzyme A formation by decreasing the deacetyla-
tion and consequent activation of acetyl-coenzyme A syn-
thetases [72]. Consequently, the formation of acetyl-
coenzyme A will be compromised, decreasing the amount 
available for the formation of ACh. Low insulin levels also 
decrease the expression of acetyl transferase, required to 
produce ACh. As with acetyl coenzyme A, the production of 
acetyl transferase lowers with decreasing insulin since IGF-I 
also regulates its production, and, as a consequence, ACh 
production is further decreased (Fig. 1) [94, 95]. 
 Another common feature of these two diseases is in-
flammation. The insulin resistance observed in T2DM indi-
viduals is associated with elevated levels of interleukin 6 
(IL-6) [96]. Likewise, AD is also associated with inflamma-
tion [97] being that Htill et al. [98] identified IL-6 in β-
amyloid plaques of AD patients. Wang et al. [99] induced 
T1DM in mice and found an increase in the generation of β-
amyloid plaques (Fig. 1). In addition, Clodfelder-Miller et al. 
[100] found that after administration of streptozotocin (STZ) 
the degree of phosphorylation of the tau protein present in 
neurons, which contributes to the formation of NFT, was 
higher in the group of diabetic animals when compared to 
the control group. Moreira et al. [56] have shown that brain 
mitochondria isolated from STZ-induced diabetic rats pre-
sent a deficit of antioxidant defenses, which increases the 
susceptibility to ROS attack. It is also thought that insulin 
resistance may lead to mitochondrial dysfunction and, con-
sequently, to energy homeostasis dysfunction due to reduced 
adenosine triphosphate (ATP) production, and to increased 
oxidative stress [80]. As sporadic AD has characteristics of 
T1DM and T2DM, Monte et al. [101] have proposed for it 
the term type 3 diabetes (T3DM), which consists of reduced 
insulin production and resistance to insulin action caused by 
modifications in the interaction between insulin and its cellu-
lar receptors. Insulin signaling failures cause disruption of 
glucose metabolism, which will increase ROS production 
(Fig. 1) [51]. This increase leads to changes in the mitochon-
drial membrane that will increase the permeability of this 
same membrane. As a result, pro-apoptotic (cytochrome c) 
proteins that activate apoptotic protease activating factor 1 
and pro-caspase 9 will be released. Thus, caspase 9 will be 
activated along with a cascade of caspase executors 
(caspases 3, 6, and 7), which will culminate in cellular apop-
tosis (Fig. 1) [102]. In addition, increased ROS activates the 
nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB) transcription factor, promoting the release of 
pro-inflammatory cytokines, such as TNF-α and interleukin 
1 (IL-1), which generates an inflammatory environment, 
consequently providing the formation of β-amyloids peptides 
(Fig. 1) [103]. The NF-kB transcription factor signaling 
pathway is also increased due to the decreased SIRT1 activ-
ity, exacerbating neurotoxicity seeing as SIRT1 is normally 
responsible for interacting with the RelA/p65 subunit of NF-
κB and inhibiting its transcription by deacetylating a critical 
lysine at position 310 [104, 105]. 
 In patients with AD who also suffer from DM, it was 
observed that the administration of exogenous insulin to-
gether with conventional antidiabetic medication (in some 
cases metformin) had effects on the decrease of β-amyloid 
plaque deposition and improved the cognitive function of the 
patients [106-108]. In 1983, Bucht et al. [15] analysed 839 
individuals with neurodegenerative diseases and, through a 
glucose tolerance test and blood glucose levels, found that 63 
of them had DM. Thus, the hypothesis of these two patholo-
gies being related emerged, although still without knowing 
in what form. Afterwards, the number of studies increased 
and, in 2008 Beeri and collaborators administered insulin in 
adults with AD and observed that the individuals who were 
submitted to a combined insulin therapy and daily admini-
stration of antidiabetic drugs (for example metformin and 
sodium–glucose cotransporter 2 inhibitors) presented a sig-
nificant decrease in the formation of β-amyloid plaques in 
the hippocampus, the entorhinal cortex, and the cerebral cor-
tex, when compared to subjects who were only on insulin or 
antidiabetic medication [106]. In this way, it is noticed that 
DM is a risk factor for AD, but the opposite is also true. One 
evidence is that β-amyloid peptide produced in individuals 
with AD inhibits the autophosphorylation of insulin recep-
tors, which will prevent the binding of insulin to its receptor 
and, as a consequence, causes insulin resistance (Fig. 1). 
Thus, it is considered that these two pathologies are inter-
connected through common mechanisms [80, 109]. 
3. POLYPHENOLS 
 Phenolic compounds comprise a wide group of natural 
compounds broadly distributed in a variety of plant-derived 
foods commonly used in our diet [45], namely in fruits, nuts, 
cereals, beverages, legumes, spices and many others. They 
exist in these plant foods as secondary metabolites that pro-
tect plants from ultraviolet radiation, oxidative stress and 
some herbivores, but also to attract insects pollinators [110]. 
Structurally, they are characterized by the presence of one or 
more aromatic rings attached to one or more hydroxyl 
groups [111]. More than 8,000 phenolic compounds have 
been identified and they are usually organized into sub-
classes (Fig. 2) [112] where inclusion criteria in each group 
may be the source, biological function or chemical structure 
[113]. A characteristic property of phenolic compounds, par-
ticularly of those whose hydroxyl groups occur in the ortho- 
or para-position, is their role in redox reactions, where they 
act as reducing agents and hydrogen donors [110]. There-
fore, polyphenols interfere with the oxidation of bio-
molecules by promptly donating protons to radicals or by 
reacting with radicals to form compounds that prevent them 
to react with other molecules [114]. Due to these actions, 
polyphenols are known as excellent antioxidant molecules. 
Indeed, there is a positive direct correlation between the an-
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tioxidant capacity of polyphenols and the number of hy-
droxyl groups present in the phenolic structure. 
3.1. Classes and Subclasses 
 The organization of phenolic compounds in classes is 
quite different according to different authors. Some authors 
have classified them into two great classes: Flavonoids and 
Non-flavonoids [115]. More frequently, the non-flavonoids 
have been divided into well-defined classes, resulting in a 
total of 5 or 6 classes [110, 111, 116]. In this review, three 
classes of non-Flavonoids - Phenolic acids, Stilbenes, and 
Curcuminoids - are distinguished regarding their chemical 
structures, health-promoting properties and biological 
relevance of their representative members (Fig. 2). 
 Flavonoids constitute the largest class of polyphenols, 
including almost half of all the phenolic compounds identi-
fied so far [111]. Most of them are characterized by the pres-
ence of two aromatic rings (A and B rings) linked by a pyra-
nic ring (C ring) and, according to the oxidation degree of 
the pyranic ring, they can be classified into 6 subclasses: 
flavonols, flavanols, isoflavones, flavanones, flavones and 
anthocyanins [112]. A representative example of each sub-
class is presented in Fig. 2. Naturally occurring flavonoids in 
foods usually exist as glycosides (bound to one or more sug-
ars) [117]. 
 Structurally, phenolic acids contain one aromatic ring 
attached to one or more hydroxyl groups and to a carboxylic 
group. They are divided into two subclasses: derivatives of 
benzoic acid and derivatives of cinnamic acid (Fig. 2). In 
foodstuffs, hydroxycinnamic acids are more common than 
hydroxybenzoic acids and both subclasses are rarely found in 
their free form, unless when foods suffer severe processing 
[118]. A representative example of each subclass is pre-
sented in Fig. 2. 
 Curcuminoids are characterized by the presence of two 
aromatic rings symmetrically linked to a β-diketone moiety. 
Despite their low abundance in foods, their health-promoting 
properties lead to the creation of this individual class of non-
flavonoids [119, 120]. 
 Stilbenes are structurally characterized by the presence of 
two aromatic rings connected through a double bond. One of 
the most well-known stilbenes is resveratrol (Fig. 2). This 
class is just found in a limited number of plants and therefore 
is present in very low quantities in the human diet [118, 121]. 
3.2. Extraction and Analysis 
 Reliable analysis of phenolic compounds is a process 
accomplished by several steps. The diversity and complexity 
of polyphenols, each one with specific physical-chemical 
and structural properties, is by itself a countless challenge to 
their extraction, purification, identification and quantifica-
tion in food products. Furthermore, even the sample type 
must be taken into count since it determines what pre-
treatment is necessary. For example, most samples are solids 
and, so, undergo a process of pre-treatment consisting of 
grinding, homogenization, air-drying or freeze-drying, 
among others. Liquid samples are first filtered or centrifuged 
[114, 122, 123]. Since most phenolic compounds are natu-
 
Fig. (2). Schematic illustration of the main chemical structures belonging to the classes and subclasses of phenolic compounds. Division of 
flavonoids into flavanols (e.g. catechin), flavones (e.g. luteolin), flavonols (e.g. quercetin), isoflavones (e.g. genistein), flavanones (e.g. hes-
peretin) and anthocyanidins (e.g. delphinidin). Classification of non-flavonoids in stilbenes (e.g. resveratrol), curcuminoids (e.g. curcumin) 
and phenolic acids, which can be divided into hydroxybenzoic acids (e.g. gallic acid) and hydroxycinnamic acids (e.g. caffeic acid). 
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rally found in their source as conjugates, a hydrolysis step is 
sometimes used to disrupt glycoside or sulphur linkages with 
the purpose to achieve the highest release of free polyphe-
nols [114, 122, 123]. To avoid degradation of native pheno-
lic compounds, samples are often dried, frozen or lyophilized 
before extraction to avoid enzymatic degradation. An effi-
cient recovery of phenolic compounds depends on the suc-
cess of the extraction step. However, it is impossible to set a 
unique extraction method for polyphenols, since this proce-
dure depends on intrinsic properties of each phytochemical, 
like the lipophilicity/polarity. Hence, there are different ex-
traction methods for phenolic compounds, but most of them 
are based on solvent extraction. The solvent can be water, an 
organic solvent (frequently methanol or ethanol), hydroalco-
holic mixtures, or liquefied gas, or combinations of them, 
under different temperatures and pressures. Solid-liquid and 
liquid-liquid extractions are the most used procedures, 
mainly because they are easy to use in common laboratories, 
efficient, and have wide-ranging applicability [120]. In cer-
tain cases where these methods cannot be applied, other op-
tions have been used as an alternative, such as Soxhlet ex-
traction, supercritical fluid extraction and microwave 
assisted extraction [114, 122, 123]. After the extraction, a 
purification/isolation step is required to purify the desired 
phenolic compounds from all the contaminants and, eventu-
ally, from other polyphenols. For that purification, solid-
phase extraction, open column chromatography and prepara-
tive high-performance liquid chromatography (HPLC) are 
the most used [123]. 
 The identification and quantification of phenolic com-
pounds can be performed by a variety of methods, namely by 
spectrophotometric, chromatographic and electrophoretic 
methods. Mass spectrometry (MS) can be coupled with these 
techniques providing incomparable chances in the identifica-
tion and structure elucidation of polyphenols [114]. Despite 
the difficulty of selecting the best method to determine phe-
nolic compounds, HPLC/DAD and liquid chromatography–
mass spectrometry (LC–MS) have been proposed by several 
authors as the most suitable techniques for this purpose [124, 
125]. In fact, LC–MS has been considered as the most effec-
tive method for qualitative and quantitative analysis and 
even for structural characterization [126]. 
3.3. Sources on Diet, Metabolism and Bioavailability 
 The dietary sources of polyphenols, which are mainly 
fruits and vegetables, and therefore, are part of an healthy 
diet, contain not only a phenolic compound but a mixture of 
several phenolic compounds in different chemical forms 
[127]. According to Commenges et al. [128], the dietary 
consumption of flavonoids (the major class of polyphenols) 
is around 14,4 mg per day. The determination of dietary 
polyphenols intake is very difficult because it varies accord-
ing to the dietary pattern of each person and because there is 
a lack of information about the number of polyphenols pre-
sent in each food, mainly in non-processed food [129]. It is 
important to note that the daily dietary intake of phenolic 
compounds is not the only concern since the antioxidant po-
tential of each polyphenol in each food is crucial for many 
bioactivities. Perez-Jimenez et al. ranked the 100 richest 
foods in terms of polyphenols, each with its respective anti-
oxidant content, being clove, peppermint, star anise, cocoa 
powder, mexican oregan, celery seed, black chokeberry, dark 
chocolate, black elderberry and chestnut the ten most rich 
[130]. Noteworthy, the total phenolic content does not di-
rectly correspond to the total antioxidant activity, since phe-
nolic compounds are not the only antioxidant compounds 
present in foods [130]. According to the nutritional recom-
mendations of World Health Organization [131], a healthy 
diet must include the consumption of at least 400 g (5 por-
tions) of fruits and vegetables a day for an adult. However, it 
is difficult to define the intake of polyphenols in a healthy 
diet. In fact, it is extremely difficult to predict their intake 
based only on the dietary patterns, once their concentrations 
in foods could vary according to numerous factors, namely 
genetic, environmental, and technologic factors [28]. 
3.3.1. Metabolism and Bioavailability 
 The absorption and metabolism of dietary phenolic com-
pounds is a crucial factor for their bioavailability, which in 
turn is imperative for the establishment of a significant bio-
logical activity. However, absorption and metabolism are 
affected by the chemical structure of the polyphenol itself 
and factors related to interpersonal variability, such as enzy-
matic activities, and systemic factors, for example age, gen-
der and pathologies. 
 Considering the largest class of polyphenols, cleavage of 
oligomeric flavonoids can occur in the stomach at low pH. 
All subclasses of flavonoids are metabolized in the jejunum 
and ileum of the small intestine and the resulting metabolites 
enter the portal vein reaching the liver where undergo further 
metabolism. The microflora of the colon degrades the fla-
vonoids into smaller phenolic acids that can also be absorbed 
into cells and tissues and some of them even cross the blood-
brain barrier [132]. Although is clear that polyphenols and 
their metabolites can cross the blood-brain barrier, reach 
brain cells and modulate brain bioprocesses, the route by 
which they cross the barrier (simple diffusion or by carrier-
mediated transport) remains unclear. However, studies in 
situ, in vitro and in silico showed that polyphenol structure 
and efflux systems influence their brain bioavailability [133, 
134]. Nevertheless, most of these metabolites are excreted in 
urine contributing to a lower bioavailability [132]. 
 Although flavonoids can be absorbed from the gastroin-
testinal tract, plasma concentrations (bioavailability) are low, 
usually much inferior to 1 M. Manach et al. [135] concluded 
that the plasma concentrations of total metabolites range 
from 0 to 4 µM with an intake of 50 mg of aglycone (the 
non-sugar component that results from hydrolysis of gly-
cosides), like quercetin, genistein or gallic acid. Moreover, 
the phenolic compounds that are more easily absorbed in 
humans are isoflavones and gallic acid, followed by cate-
chins, flavanones, and quercetin glucosides, with different 
kinetics [135]. At concentrations as low as 4 µM, most phe-
nolic compounds are unlikely to have a significant and direct 
antioxidant effect when ingested in the normal amounts of a 
healthy diet [111]. Thus, much of the evidence on the bene-
ficial effects of dietary polyphenols is derived from experi-
ments conducted in vitro or in animal models using concen-
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trations much higher than those generally found in the hu-
man diet [136]. However, polyphenols ingestion has been 
linked with a decrease in the incidence of DM and AD in 
vivo [137, 138], which suggests its actions beyond the usual 
antioxidant activities [111]. 
3.4. Bioactivities and Bioeffects 
 Polyphenols have been implicated as potential preventive 
and curative agents for a number of diseases, such as AD 
[110], Huntington's disease [139], Parkinson's disease [140], 
chronic fatigue syndrome [141], hypercholesterolemia [142], 
DM [25], stroke [143], several cancers [121], cardiovascular 
disease [144], autism [145], vitiligo [146], among others 
[147]. Despite being phenotypically different, these patholo-
gies have oxidative stress and inflammation as common fac-
tors. In order to cope with an excess of free radicals pro-
duced in oxidative stress, humans have endogenous mecha-
nisms to maintain redox homeostasis but somehow these 
mechanisms fail or decompensate in pathologic contexts. 
This is why exogenous sources of antioxidants capable of 
dealing with the oxidative stress are so important. Among 
these, dietary polyphenols have been extensively studied for 
their strong antioxidant capabilities. Among the several pos-
sible mechanisms, the radical elimination hypothesis postu-
lates that polyphenols specifically scavenge free radicals by 
binding to them and blocking their deleterious effect [147]. 
Although the antioxidant effect is most often reduced only to 
scavenging and blocking free radical effects, strategies for 
antioxidant activity go beyond free radicals neutralization 
(Fig. 1) and include other activities, such as enzymatic con-
trol, iron chelation, regulation of signaling pathways and 
intervention in the cell cycle [116]. All these bioactivities 
together allow polyphenols to have more than antioxidant 
properties but also, anti-inflammatory, probiotic and immune 
system and epithelium modulator properties [148]. The bene-
ficial effects of polyphenols in many diseases is largely due 
to their capability of regulating signaling pathways disease-
related, such as SIRT1 [149], PGC-1α [38, 150], AMPK 
[151], mitogen-activated protein kinases (MAPK) which in 
mammals include the extracellular signal-regulated kinases 
(ERK), the p38 MAPKs, and the c-Jun NH2-terminal 
kinases, NF-kB, activator protein 1, canonical Wnt and pro-
tein kinase C (PKC) [147, 148]. These pathways play a key 
role in many biological functions, such as cell proliferation, 
apoptosis, transcription regulation, inflammation, cell signal-
ing, immune responses, learning and memory [147, 148]. 
Commonly, the role of phenolic compounds in signal path-
ways regulation is due to redox-sensitive modulation of dif-
ferent signaling cascades [116]. By modulating these signal-
ing pathways, that are indeed engaged in several pathologies 
and are the targets in many therapeutic strategies, polyphe-
nols appear as promising therapeutic/protective agents in 
various pathologies [152]. 
4. POLYPHENOLS AS PROTECTIVE AND 
THERAPEUTIC AGENTS IN ALZHEIMER’S 
DISEASE AND DIABETES MELLITUS 
4.1. Catechins 
 Catechins are polyphenols of the flavanol family and are 
characterized by strong antioxidant power. They are present 
in green and white teas, cocoa and red wine [24]. The most 
well-known are catechin, EC, epicatechin gallate (ECG), 
epigallocatechin (EGC) and epigallocatechin-3-gallate 
(EGCG) and they have been studied by several researchers in 
an attempt to understand their neuroprotective capacity in 
AD [24]. A previous study showed that green tea consump-
tion was associated with a lower risk of cognitive problems 
[153]. EGCG (along with EC, ECG and EGC [154]) is one 
of its main constituents [153] and has been a target of re-
search interests due to its antioxidant capacity, which gives it 
neuroprotective and antidiabetic effects. EGCG is involved 
in the control of apoptosis by inhibiting the expression of 
pro-apoptotic genes, such as Bcl-2-like protein 4 (Bax) and 
Bcl-2-associated death promoter, inducing anti-apoptotic 
genes, such as the known B-cell lymphoma 2 (Bcl-2), Bcl-2-
like protein 2 and B-cell lymphoma-extra, and inhibiting the 
activity of caspase-3, preventing neuronal cell death (Fig. 1) 
[24]. EGCG activates the phosphatidylinositol 3 kinase/ pro-
tein kinase b (PI3k-Akt) signaling pathway promoting cell 
survival and "waking up" cells from the state of senescence. 
It has the ability to restore the activity of PKC, which will 
increase the release of a non-amyloidogenic soluble precur-
sor, which will counteract the formation of β-amyloid 
plaques characteristic of AD. In addition, it protects the brain 
against inflammation, prevents memory impairment and re-
duces oxidative stress. Throughout life, iron accumulates 
progressively in regions, such as the putamen, prefrontal 
cortex and sensory cortex. With aging this is converted into a 
substance containing iron with higher reactivity, hemosid-
erin, promoting oxidative stress. The EGCG exhibits neuro-
protective effects due to its ability to chelate the metal ions 
avoiding the formation of free radicals [153]. In AD, the 
cholinergic system of the brain is considered very important. 
Its decline is associated with memory loss, and therefore the 
drug treatment used to combat this disease inhibits cho-
linesterases, such as AChE and BChE. Okello et al. [155] 
verified through in vitro studies the effect that green and 
black teas (black tea main constituents are theaflavins, that 
result from the oxidation and dimerization of catechins 
[154]) could have on the inhibition of these two cho-
linesterases. The authors realized that the inhibitory activity 
of these two teas was dose-dependent, in the range of con-
centrations which were used (0-0.3 mg/mL). For AChE, the 
IC50 values for green and black teas were 0.03 and 0.06 mg / 
mL, respectively. In the case of BChE, an IC50 value of 0.05 
mg / mL was obtained for both teas. In this way, the con-
sumption of these teas seems to delay or inhibit the hydroly-
sis of ACh, allowing this neurotransmitter to exist in greater 
concentration in the brain and during a longer period (Fig. 1). 
 In DM, EGCG inhibits hepatic production of glucose, 
controls gluconeogenesis, minimizes β-cell damage and in-
creases insulin sensitivity [156]. Wolfram et al. [157] 
showed that it negatively regulates the expression of phos-
phoenolpyruvate carboxykinase messenger ribonucleic acid, 
an enzyme involved in gluconeogenesis. In addition, EGCG 
increases the levels of glucose transporter genes 1 and 4 
(GLUT1, 4) and inhibits the genes involved in fatty acids, 
triacylglycerols and cholesterol biosynthesis, which results 
in less DM complications. It increases the transcription fac-
tor (erythroid-derived 2) -like 2 that regulates the expression 
of antioxidant proteins that protect against oxidative stress 
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[158]. EGCG was also shown to be a positive regulator of 
SIRT1 expression in H9c2 cardiomyocyte cells. Wu et al. 
[149] found that cultures of diabetic cells with EGCG (10 
mM) showed increased SIRT1 expression relative to the 
group of cells not exposed to EGCG. They suggested that 
EGCG could enhance the expression of SIRT1 that mediates 
the effects of oxidative stress by regulating genes that trans-
late into antioxidants. It also increases the activity of en-
dogenous antioxidants, such as superoxide dismutase (SOD), 
catalase (CAT) [159] and glutathione peroxidase (GSH-Px) 
that have the function of neutralizing free radicals, guaran-
teeing the body's homeostasis [160]. In addition, EC, EGC 
and EGCG inhibit plasma proteins carbonylation (an irre-
versible modification in oxidized proteins) that results from 
ROS action characteristic of the hyperglycaemic state (Fig. 
1) [160]. The anti-inflammatory properties are further high-
lighted since EGCG counteracts the effects of cytokines in 
the insulin secretion [161]. EGCG increases insulin secretion 
and reduces blood glucose levels and, thus, ameliorates hy-
perglycaemia (Fig. 1) [162]. Taking into account all these 
properties of the EC, ECG, EGC and EGCG, the study of 
foods and teas containing them is a matter of interest, since 
their consumption may be an alternative method to combat 
chronic diseases, such as DM and AD [24, 153, 161]. 
 In order to reduce hyperglycaemia, glucosidase inhibi-
tors, such as acarbose and miglitol, which act on α-amylase 
and α-glycosidase (two intestinal enzymes that hydrolyse 
carbohydrates) are used. However, these inhibitors cause 
great side effects, namely intestinal disturbances. Thus, Yil-
mazer-Musa et al. [163] studied the potential of green tea, 
white tea and individual catechins (EC, EGC, ECG, EGCG) 
to inhibit α-amylase activity (from human saliva) and α-
glycosidase (from Saccharomyces cerevisiae). These authors 
noted that green tea had a similar percentage of acarbose-like 
α-amylase inhibition, while white tea, EC, EGC, ECG and 
EGCG showed approximately half of that percentage. When 
comparing the inhibition of α-glucosidase with that con-
ferred by acarbose, both green and white teas had similar 
percentages, whereas those of ECG and EGCG were slightly 
higher. However, EC and EGC had lower inhibition power 
than acarbose and cannot be considered as strong inhibitors 
of this enzyme. 
 Among the different types of tea, white tea contains the 
highest catechins content, especially of EGCG [164-166]. 
This tea is also composed of other polyphenols, proteins, 
polysaccharides, minerals, organic acids, lignins and meth-
ylxanthines, such as caffeine, theophylline and theobromine 
[167, 168] and has shown beneficial effects in several tissues 
of prediabetic animals. Our research group has been devoted 
to the study the effects of the daily consumption of white tea 
in various tissues, using an animal model of Wistar rats. 
Animals were divided into three groups: in two of the 
groups, prediabetes was chemically induced by using STZ 
(40 mg / kg), while the third group acted as a control (was 
injected only with vehicle solution in an equivalent volume). 
Subsequently, one of the groups with prediabetes consumed 
white tea during two months, while the other did not, receiv-
ing only water [165, 169-171]. As expected, prediabetic rats 
developed mild blood hyperglycaemia, glucose intolerance 
and insulin resistance. Interestingly, the daily intake of white 
tea restored glucose tolerance and insulin sensitivity. Several 
in vitro studies, animal experiments and clinical observations 
suggest that tea catechins are the main responsible for it 
[172-174]. Moderate hyperglycaemia led to less lactate ac-
cumulation in the brain cortex, due to an increase in its me-
tabolism (increased LDH activity) [165]. Lactate is consid-
ered an important metabolic fuel for the cerebral cortex in 
stressful situations, such as prediabetes, which is in agree-
ment with the decrease noted in the untreated group. Predia-
betes also reduced the antioxidant capacity of the brain cor-
tex, increasing the oxidative damage in lipids and proteins 
but white tea was able to restore the total antioxidant capac-
ity, strongly decreasing lipid peroxidation and protein oxida-
tion. These neuroprotective effects may be attributed to 
EGCG and other catechins [175-177]. In addition, the ex-
pression of CAT, an endogenous antioxidant enzyme consid-
ered as one of the most important antioxidant defenses in this 
tissue, was diminished in prediabetic rats, but white tea re-
established its expression. Thus, all these results allowed us 
to understand that the daily consumption of white tea, rich in 
catechins, maybe a cheap and natural alternative to improve 
the deleterious effects caused by DM and reduce complica-
tions in the brain. Moreover, Alves et al. [171] studied the 
benefits of white tea intake in the heart of prediabetic ani-
mals. As expected, prediabetes also reduced the heart anti-
oxidant capacity, increasing the oxidative damage in lipids 
and proteins. Once again, white tea improved the total anti-
oxidant capacity and restored lipid peroxidation levels. 
These cardioprotective effects may be attributed to tea cate-
chins [178, 179]. 
 In addition to the effects observed in brain and cardiac 
tissues, the consumption of white tea also causes alterations 
in the reproductive function. Oliveira et al. [145] found that 
white tea intake improved the oxidative parameters of tes-
ticular tissue, resulting in increased antioxidant potential, 
decreased levels of lipid peroxidation and protein carbonyla-
tion. Also in the epididymis, Dias et al. [170] reported that 
levels of phosphofructokinase 1 (an enzyme involved in gly-
colysis) were decreased in the prediabetic animals. Interest-
ingly, these levels were restored by white tea consumption. 
4.2. Luteolin 
 Luteolin is a flavone present in parsley, celery, orange 
and spices [121]. Its chemical structure allows it to act as an 
antioxidant, a free radical scavenger, an anti-inflammatory 
agent and is thought to be able to inhibit PKC [180]. Its anti-
oxidant activity may be useful for treating diseases related to 
oxidative stress, such as DM and AD [180]. Wang et al. 
[181] performed a study in male Wistar rats, that were sub-
sequently divided in 6 groups, in which 3 corresponded to 
controls for diverse experiment conditions and in the other 3 
groups, STZ was injected in order to induce AD. In the 
fourth and fifth groups, besides STZ, luteolin was injected 
intravenebroventricularly at a dose of 10 and 20 mg / kg re-
spectively. In order to assess memory impairment, the 
authors performed the Morris water maze test in which, days 
before, the animals had learned in order to gain memory of 
how to reach the platform. The results showed that the ani-
mals in which luteolin was administered remained longer in 
the quadrant where the hidden platform was located, regard-
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less of the dose of luteolin used. This demonstrates that these 
animals have lower memory impairment than the non-
injected ones and that these can have an improved learning. 
Therefore, these researchers concluded that this polyphenol 
improved cognitive function and, consequently, was consid-
ered neuroprotective. In this study, the authors suggested that 
this could be, at least in part, explained by the antioxidant 
activity of this polyphenol through the inhibition of free 
radicals production. It has been demonstrated that luteolin 
eliminates ROS (Fig. 1) not only by inhibiting the ROS-
MAPK-mediated mechanism [182] but also by inhibiting the 
expression of NADPH oxidase 4, p22phox, intercellular ad-
hesion molecule 1 and vascular cell adhesion molecule 1 
[183]. Furthermore, luteolin prevents the dispersing of the 
characteristic plaques of AD through the inactivation of the 
glycogen synthase kinase-3 alpha isoform which increases 
the phosphorylation of PS1 protein, forming a compound 
that will reduce the PS1-APP interaction and hence the gen-
eration of β-amyloid plaques (Fig. 1) [181, 184]. 
 Concerning DM, studies have demonstrated the antidia-
betic activity of luteolin. A study by Wang et al. [180] 
showed that administration of luteolin for 8 weeks in dia-
betic Sprague-Dawley rats decreased blood glucose levels. In 
addition, it also increased SOD activity and decreased 
creatinine and blood urea nitrogen in the kidneys. This evi-
dence suggests that luteolin prevents diabetic nephropathy, 
which may involve a SIRT1-mediated mechanism, seeing as 
luteolin is capable of increasing SIRT1 expression [185] and 
this deacetylase has been found to have renal protective ef-
fects [36, 186]. hyperglycaemia, insulin resistance, renal 
lipid accumulation, inflammation and oxidative stress result 
in kidney cell injury, leading to the development and pro-
gression of nephropathy. Therefore, SIRT1 anti-apoptotic, 
anti-oxidative and anti-inflammatory actions, as well as its 
regulation of mitochondrial biogenesis, autophagy and 
metabolism, protects against renal cellular injury [36]. Also 
Zang et al. [187] concluded that this flavone improved blood 
glucose levels and insulin resistance in KK-Ay (TaJcl) male 
mice. The ability to decrease insulin resistance arises from 
the decrease that luteolin causes in TNF-α, a pro-
inflammatory cytokine that affects β-cell function and in-
duces resistance (Fig. 1). Another study by Li et al. [188] 
showed that after administration of luteolin by intraperito-
neal injection in adult male Sprague-Dawley rats there was a 
decrease in blood glucose, an increase in the activity of anti-
oxidants, such as SOD, GSH-Px and CAT, and a decrease in 
ROS that was more salient with the administration of higher 
amounts of luteolin (100 and 200 mg / kg). This flavone was 
also able to increase nuclear factor Nrf2, a defense mecha-
nism against oxidative stress. On the other hand, Kim et al. 
[185] found in Human monocytic cells subject to a condition 
of hyperlycemia the effects of luteolin in the expression of 
SIRT1 and FOXO3a. They suggested that hyperglycaemia 
negatively regulates the SIRT-FOXO3a path resulting in the 
production of ROS. However, it was found that cells submit-
ted to luteolin treatments had higher levels of SIRT1 and 
FOXO3a expression and consequently decreased ROS pro-
duction, suggesting that this polyphenol could be a potential 
agent for the prevention and treatment of DM. Thus, it is 
concluded that luteolin has neuroprotective, anti-
inflammatory, antidiabetic and antioxidant activity, and is 
very beneficial to reduce ROS, one of the main problems of 
DM and AD. 
4.3. Quercetin 
 Quercetin is a flavonol especially found in products such 
as blueberries, apples, broccoli, beans and tea [121]. It can 
cross the blood-brain barrier and thus contribute to the pro-
tection of brain cells in AD [189]. In addition, the levels of 
β-amyloid plaques, as well as the reactivity of some glial 
cells, decreased with quercetin [189]. In one study by 
Sabogal-Guaqueta et al. [189], 25 mg/kg of quercetin were 
administered through intraperitoneal injections in Homozy-
gous 3xTg-AD and non-transgenic mice with AD for three 
months, and the deposition levels of these plaques decreased 
relatively to the untreated group. In agreement with these 
results the fragmented APP levels also decreased in the 
treated group, which explains the smaller plaque deposition. 
Furthermore, it is also known that this polyphenol increases 
the levels of antioxidant defenses, namely GSH in astrocytes 
and neurons, thus contributing to the reduction of oxidative 
stress [189]. With these findings, it is hypothesised that it 
works as a neuroprotector for individuals with AD [189]. 
 Quercetin is also an AChE inhibitor. In fact, in a study 
performed by Tota et al. [190] in which AD-induced Swiss 
albino mice were used, the effect of quercetin on the inhibi-
tion of AChE activity was observed. In animals with AD the 
levels of this enzyme are increased which implies a decrease 
in ACh (Fig. 1). This decrease is significantly associated 
with AD complications, so it is important to find natural al-
ternatives to prevent these effects. When using 5 mg of quer-
cetin per kg, these authors found that the activity of AChE 
decreased significantly. However, lower doses (2.5 mg / kg) 
had no effect. This demonstrates that although quercetin has 
effects on the control of AChE activity, this is dependent on 
the dose ingested, which suggests the need for further studies 
to define the most appropriate dose to have positive effects 
on humans. 
 SIRT1 is also affected by quercetin consumption, as Sa-
rubbo et al. [191] found that the daily consumption of this 
polyphenol (20 mg/kg) by young and elderly Sprague-
Dawley rats for 28 days, lead to increased levels of SIRT1 in 
the elderly rats. SIRT1 plays a key role in regulating mem-
ory, seeing as it promotes ACh production, and when SIRT1 
levels is impaired cognitive abilities are also affected. In 
addition, it promotes α-secretase activity [70] and regulates 
NF-κB signaling, reducing pro-inflammatory responses 
[191]. Thus, an agent capable of enhancing SIRT1 may im-
prove the quality of life of patients with AD by reducing the 
levels of β-amyloid plaques and reducing NF-κB levels pre-
venting increased inflammation [191]. However, the mecha-
nism by which SIRT1 levels increases with quercetin con-
sumption is still unclear. It is known that oxidative stress is 
one of the main factors for the decrease of levels of SIRT1 
thus, quercetin due to its antioxidant properties may avoid 
the consequences of this stress maintaining the levels of 
SIRT1. 
 But the benefits of quercetin are not limited to AD alone. 
There is also evidence that in DM it has anti-inflammatory 
and antidiabetic capabilities in which quercetin, through the 
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translocation of GLUT4 and the phosphorylation of AMPK, 
decreases plasma glucose levels [192]. In the small intestine, 
it decreases the activity of maltase and glucose transporter 2 
(GLUT2) favouring the decrease of the absorption of glucose 
at the intestinal level, thereby restoring glycaemia [193]. As 
it is an antioxidant by nature, it removes free radicals (Fig. 1) 
[194] through the increase of antioxidant defenses [195], 
thus reducing lipid peroxidation since there are less free 
radicals available to damage lipids [196]. However, the low 
hydrosolubility, low permeability and short half-life are ma-
jor limitations of this polyphenol. Nevertheless, it still has 
beneficial effects on the regeneration of β-pancreatic cells. In 
part, the destruction of these cells is caused by the surround-
ing inflammatory environment in which there is a release of 
cytokines that inhibit insulin secretion. ROS also contribute 
to this DM problem, once they activate NF-kB, which leads 
to increased p28, resulting in apoptosis. Due to its anti-
inflammatory and antioxidant potential, quercetin contributes 
to the regeneration of these cells [197]. 
 In sum, quercetin has properties that bring many benefits 
for DM and AD, such as neuroprotection, free radicals scav-
enging, anti-inflammatory activity and antidiabetic ability. 
4.4. Genistein 
 Genistein is an isoflavone that can be found in products 
such as soybeans (and their derivatives) [121]. It is known 
that it is able to cross the blood-brain barrier because it 
causes the reduction of the toxicity of β-amyloid plaques and 
the decrease of neurons apoptosis, which is responsible for 
the great loss of neurons in AD [198]. Therefore, it is pre-
sumed that the reduction of this apoptosis contributes to the 
improvement of the symptoms. Studies in female Sprague-
Dawley rats indicate that the intragastric administration of 30 
and 60 mg/ kg of genistein reduces the expression of cyto-
chrome c, caspase 3 and Bax leading to a decrease in the 
number of apoptotic cells and thus contributing as a protec-
tive factor for AD (Fig. 1) [198]. In addition, genistein pro-
tects β-pancreatic cells from the high toxicity of cytokines 
because it induces the inhibition of inducible gene expres-
sion of nitric oxide synthase, nitric oxide production and 
signal transducer suspension (extracellular signal–regulated 
kinases 1/2 and Janus kinase/signal transducer and activator 
of transcription). It also protects pancreatic cells expressing 
the estrogen receptor β through the same receptor along with 
Bcl-2. It acts as an antioxidant by inducing the expression of 
enzymes, such as manganese SOD and CAT, and increasing 
the proportion of reduced GSH / oxidized GSH. Thus, it pro-
vides the activity of the antioxidant enzymes leading to the 
decrease of ROS (Fig. 1) [199]. It also has an anti-
inflammatory effect because it reduces the expression of 
TNF-α and pro-inflammatory cytokines [200]. Furthermore, 
the consumption of genistein (1 mg/kg) for 8 weeks by dia-
betic rats contributed to the increase of SIRT1 levels and 
decreased expression of NF-κB and IL-1β. Thus, through the 
expression of SIRT1, treatment with genistein reduced tissue 
inflammation [201]. Studies have shown that it reduces in-
flammation caused by DM at the level of the retina, once this 
polyphenol decreases the tyrosine kinase and stimulates 
ERK and p38 dependent pathways [202]. However, one of 
its main problems is the dosage since the concentrations used 
in in vitro studies are always higher than those ingested in 
foods. To overcome this problem, some studies are already 
being conducted in order to find other plant-derived com-
pounds that can be used together in order to increase poly-
phenol efficiency [203]. 
4.5. Resveratrol 
 Resveratrol is a non-flavonoid polyphenol of the stilbene 
class, that can be found in grapes, berries and red wine [121]. 
It is considered a plant antibiotic that is produced when 
plants are with a fungal infection or under environmental 
stress, and it exists in the form of two isomers: trans- and 
cis-resveratrol. It is known that the former is non-toxic and 
has a higher potential. Resveratrol can overcome the blood-
brain barrier [204] and studies in patients indicate that it in-
duces neuroprotective effects through its anti-inflammation 
properties [205]. In addition, a study in adult male albino rats 
showed that resveratrol exhibits anti-inflammatory properties 
in AD [206]. However, its neuroprotective abilities depend 
on the doses at which it is consumed. It is able to protect 
cellular components from the damage caused by oxidative 
stress since it has a direct action on ROS (Fig. 1), which is 
largely due to its antioxidant power, since it promotes the 
activity of several antioxidant enzymes such as SOD, CAT, 
GSH-Px and glutathione reductase [207]. Oxidative stress 
can damage proteins, lipids, nucleic acids, and others. Over 
time it leads to irreversible neuronal damage. The use of 
resveratrol, in addition to having a protective role against 
oxidative stress, also improves the recovery of brain tissue 
by modulating glial functions, such as glutamate uptake ac-
tivity, GSH content and S100 calcium-binding protein B 
secretion [204]. It also has the characteristic of acting on p38 
preventing the activation of caspase 3 and, in this way, re-
ducing the apoptosis of neuronal cells (Fig. 1) [204, 208]. At 
the level of β-amyloid plaques, it avoids their aggregation as 
it promotes non-amyloidogenic processing of APP. As ex-
plained above, these plaques are formed from the proteolysis 
of APP through cleavage by the β- and γ-secretase. However, 
resveratrol promotes proteolysis through α-secretase, there-
fore preventing the formation of these plaques [204]. Al-
though the mechanisms behind its action as an anti-
amyloidogenic are not fully understood, studies show that 
resveratrol consumption results in AMPK activation, and 
consequently on SIRT1 activation, which may be a potential 
pathway by which autophagy and lysosomal clearance of β-
amyloid [209], as well as α-secretase activity are promoted 
[70]. However, a study on AβPP/PS1 mice concluded that 
resveratrol reduction of β-amyloid deposition was due to 
increased intracellular proteasomal activity [210]. Resvera-
trol SIRT1-mediated neuroprotective effect was also previ-
ously found in p25 transgenic mouse, a model of AD, where 
resveratrol administration intravenebroventricularly (5 
mg/ml) lead to reduced neurodegeneration in the hippocam-
pus, prevented learning impairment, and decreased acetyla-
tion of PGC-1α and p53, known substrates of SIRT1 with a 
role in neuronal metabolism, detoxification of ROS and 
apoptosis [211]. In addition, Sarubbo et al. [212] also veri-
fied the brain anti-aging effects of resveratrol notably 
through the activation of SIRT1 and the modulation of in-
flammation by signaling pathways such as NF-κB. 
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 In DM, studies indicate that resveratrol has the capacity 
to modestly reduce hyperglycaemia and also lead to some 
improvements in insulin sensitivity in prediabetic patients, 
namely through the activation of AMPK [213]. This action 
resembles that of current drugs used to treat DM (for exam-
ple metformin [214]), which activate AMP-activated protein 
kinase. This, in turn, will activate the PI3k-Akt pathway, 
which leads to an increased phosphorylation of glycogen 
synthase kinase-3, and consequently, its action is inhibited 
and expression of genes, such as phosphoenolpyruvate car-
boxykinase (PEPCK) and glucose-6-phosphatase (G-6-Pase), 
in the liver decreases, therefore reducing gluconeogenesis 
[23]. In adult patients, the consumption of 1g / day of res-
veratrol was sufficient to verify these benefits. Resveratrol 
beneficial effect on insulin sensitivity was also associated 
with SIRT1 activation and consequent PGC-1α deacetyla-
tion, which affects mitochondrial metabolism [215]. Re-
duced mitochondrial oxidative capacity can cause insulin 
resistance through oxidative stress, thus, PGC-1α deacetyla-
tion and consequent activation lead to mitochondrial bio-
genesis, reducing oxidative stress caused by mitochondrial 
dysfunction [215]. 
 Furthermore, it has been found that this polyphenol can 
affect the concentration of insulin in the blood [213]. Under 
normal physiological conditions, the secretion of insulin re-
quires a set of processes that begin with the entry of glucose 
into the cells through GLUTs. The process then begins with 
hyperpolarization of the mitochondrial membrane in which 
ATP is formed increasing the ratio ATP/adenosine diphos-
phate (ADP). Potassium channels, sensitive to ATP, are 
closed and the membrane is depolarized. The calcium chan-
nels open and check the entrance of this ion to the cells that 
contribute to the secretion of insulin. Resveratrol acts by 
decreasing ATP formation which decreases the ATP/ADP 
ratio and attenuates the secretion of pancreatic insulin. How-
ever, the decrease in insulin secretion caused seems to be 
reversible since it does not cause permanent disturbances in 
the cells [216]. At the cytokines level, the action of resvera-
trol is also notorious since it decreases the release of TNF-α, 
IL-1 and IL-6 (Fig. 1). In this way, the expression of nitric 
oxide synthase decreases, contributing to the decrease of 
nitric oxide production and to the decrease of inflammation 
[217]. As in AD, in DM it also leads to an improvement in 
the parameters of oxidative damage, once it increases the 
activity of the SOD, CAT and GSH-Px. In a study in mice, 
in which these ingested 22.4 mg / kg of resveratrol, it was 
also verified the increase of the sensitivity to insulin, thus 
improving its action [218]. All these data allow the percep-
tion of the beneficial properties of resveratrol and that in the 
future it may be used, in combination with other antidiabetic 
treatments, in the prevention and treatment of DM [216]. 
 Resveratrol is the polyphenol with the most known 
SIRT1 association, being identified as an activator of this 
deacetylase, which has beneficial effects in both AD and 
DM. However, it should be noted that recent studies show 
that resveratrol may not be a direct activator of SIRT1 [219], 
or at least, may not be an allosteric one. Instead, it is sug-
gested that resveratrol effect on SIRT1 may be indirect and 
through AMPK pathway activation [37] or that resveratrol 
may be a protein-substrate interaction stabilizer necessary for 
SIRT1 activation [220]. Nevertheless, SIRT1 appears to be 
required for resveratrol metabolic functions involving 
AMPK and PGC-1α [38, 150]. 
4.6. Curcumin 
 Curcumin is a non-flavonoid of the curcuminoid family 
and is found in saffron [221]. This phytochemical is sensitive 
to UV-vis light, high pH and oxygen [222]. Its half-life in 
human blood lasts about 8 hours and the half-life increases 
with decreasing pH [223]. In AD, studies showed that con-
sumption of curcumin leads to a lower incidence of the dis-
ease [224, 225]. It has also been discovered that its consump-
tion brings improvements to cognitive function and its power 
to reduce free radicals levels (Fig. 1) is superior to that of 
vitamin E [224]. Garcia-Alloza et al. [226] found a reduction 
in the oxidative damage and the levels of β-amyloid plaques. 
In fact, some of the existing plaques were eliminated and the 
formation of new ones was prevented. This decrease in 
plaque production might be a result of the regulation of 
phosphorylation of the glycogen synthase kinase-3 beta en-
zyme, which appears to decrease the activity of PS1 and γ-
secretase. Other studies, namely in BALB/c mice have ad-
dressed the anti-inflammatory capacity of curcumin, once it 
inhibits IL-1 signaling [227], and in primary cultured pre-
frontal cortical neurons found that curcumin prevents the 
cellular apoptosis, through the inactivation of caspase 3 
[228]. 
 In DM, curcumin controls blood glucose levels [229]. In 
fact, curcumin improves insulin sensitivity and fasting glu-
cose levels since, as resveratrol, it decreases the expression 
of G-6-Pase and PEPCK, consequently reducing glu-
coneogenesis. It also decreases the synthesis of fatty acids, 
cholesterol and triglycerides. Despite the mechanism by 
which curcumin acts is not fully described, there are at least 
three possible modes of action. It can act at the intestinal 
level by inhibiting the absorption of cholesterol; cholesterol 
can be eliminated from the blood by the low density lipopro-
tein receptor, whose activity is increased by curcumin; or 
curcumin can increase the activity of enzymes that degrade 
cholesterol. It is thought to have a greater influence on intes-
tinal absorption, but there are still no certainties [230]. In 
addition to these changes, TNF-α and IL-1 levels are reduced 
in curcumin studies, contributing to anti-inflammatory prop-
erties (Fig. 1) [231]. In a work by Kumar et al. [232], in 
which the development of diabetic cataracts in male Wistar-
NIN rats was studied, the authors verified that a diet with 
0,01% of this curcuminoid was beneficial because it reversed 
lipid oxidation, increased the reduced GSH and the general 
activity of antioxidant enzymes. Also, it is known to be able 
to improve insulin resistance by acting on TNF-α release 
[233]. 
 In a study by Jiménez-Flores et al. [151] treatment of 
mice db/db with 0.75% curcumin has been shown to de-
crease NF-κB expression in hepatic tissue, a key regulator of 
the inflammatory response. In addition, AMPK expression, 
which is known to be decreased in diabetic rats, was in-
creased after treatment. AMPK inhibits hepatic glucose pro-
duction and is associated with SIRT1, playing an important 
role in the lipid metabolism of hepatocytes. Therefore, its 
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modulation by curcumin may be a mechanism involved in 
the beneficial effects caused by this phenolic compound on 
DM. 
 In sum, the aforementioned evidence demonstrated the 
great antioxidant, anti-inflammatory, neuroprotective and 
anti-hyperglycaemic capacities of curcumin and how it may 
be an alternative to counteract both AD and DM. 
4.7. Gallic Acid 
 Gallic acid belongs to the non-flavonoid class and to the 
hydroxybenzoic acids family. It can be found in fruits, such 
as pomegranate, grapes and some berries, in chocolate, nuts, 
wine and green tea [121]. This phytochemical has several 
activities including antioxidant, anti-inflammatory, anti-
hyperglycaemic and cardioprotective actions [234]. Hajipour 
et al. [235], when studying the effects of gallic acid in AD, 
found that it has an antioxidative activity that decreases the 
brain levels of ROS. Also, González-Sarrías et al. [236] car-
ried out an in vitro study to understand the effect that this 
phenolic compound had on ROS levels, redox activity and 
apoptosis induced by oxidative stress. Those authors found 
that it significantly decreased hydrogen peroxide-induced 
cytotoxicity by preventing the production of free radicals 
that would induce the activation of caspase 9, which in turn 
leads to the activation of caspase 3, resulting in the activa-
tion of the apoptotic pathway (Fig. 1). Gallic acid restores 
the redox system, leading to increased reduction capacity 
and, therefore, restoring the antioxidant defense system. 
 Patel et al. [234] studied the effect of DM on rats and 
how gallic acid could contribute to improve their condition. 
The authors studied the ability of gallic acid to influence the 
levels of glucose, insulin, triglycerides, and cholesterol in the 
heart of these rats. In this way, those authors observed that 
this phytochemical produces an increase of the endogenous 
antioxidant enzymes SOD, GSH and CAT in the heart and 
diminishes the peroxidation of lipids. Moreover, it signifi-
cantly reduces glucose levels and increases insulin levels. In 
a study by Doan et al. [237] intraperitoneal administration of 
gallic acid (10 mg/kg) has been shown to decrease insulin 
resistance in C57BL/6 mice. The authors related this de-
crease with the activation of the AMPK pathway and conse-
quently of SIRT1 suggesting that this phytochemical may be 
an ally in the treatment of metabolic diseases. In addition, 
they mention that gallic acid can activate the Akt pathway 
and decrease gluconeogenic genes, such as PEPCK and  
glucose 6-phosphatase, contributing to lower glycaemic and 
insulin resistance levels [237]. 
 Benefits were also found at the level of cardiomyopathy, 
as it significantly reduces blood pressure, contraction force 
and increases the cardiac frequency. Gallic acid is also able 
to reduce free radicals resulting in a decrease in oxidative 
stress (Fig. 1) [234]. Also, in the brains of diabetic rats it 
revealed the ability to reduce free radicals levels and inhibit 
lipid peroxidation. It decreased oxidative stress and protected 
β-pancreatic cells, which caused a decrease in blood glucose 
levels. As in the heart, at the brain level it also increased the 
activity of enzymes, such as SOD, CAT and GSH, which 
demonstrates its antioxidant properties [238]. Due to these 
antioxidant and anti-inflammatory properties, some pharma-
ceutical companies already use it in food supplements 
(mainly as an antioxidant agent) [239]. 
 Although there are already several studies in both AD 
and DM that prove the various properties of this phenolic 
acid, there is a consensus that it is still necessary to continue 
investigating the mechanisms underlying these properties 
and to verify if the concentration present in the foods are 
sufficient to confer all these benefits [235, 236]. 
4.8. Therapeutic Potential 
 In view of the protective effect of polyphenols, these 
phytochemicals are considered to have a huge preventive and 
therapeutic potential for DM and AD. DM is a chronic dis-
ease and can be controlled with oral hypoglycaemic agents 
or insulin administration depending on the type of DM, 
through a healthy diet and regular exercise. However, phar-
macological therapy is costly, requires patient training and 
high-adherence to avoid side effects [31]. Furthermore, in-
creasing morbidity, mortality and the rising prevalence of 
DM complications reveals that the current pharmacotherapy 
is not sufficient and supplementary treatments that increase 
the effectiveness of the therapy are needed for the manage-
ment of DM [25]. In this context, alterations in lifestyle, es-
pecially in dietary habits, can be vital, as they are easy and 
safe to implement. It has been shown that a healthy diet can 
help to prevent the development of DM and/or can delay 
complications associated with the disease [31]. 
 The high consumption of polyphenols-enriched foods has 
been associated with a lower risk of DM. In a cohort study of 
elderly people (437 men and 500 women; aged between 65 
and 100 years) living in Mediterranean islands (from Cyprus, 
Mitilini, Samothraki, Kefalonia, Crete, Corfu and Zakynthos 
islands), long-term tea intake was associated with reduced 
levels of fasting blood glucose and lower prevalence of DM 
[137]. Meanwhile, Wedick et al. [240], with data from three 
US cohort studies, observed that a higher consumption of 
anthocyanins and anthocyanin-enriched foods (e.g. blueber-
ries, red apples and strawberries) was associated with a 
lower risk of T2DM. A meta-analysis analysed data from six 
prospective cohorts and showed that individuals with the 
highest intake of flavonoids had a 9% lower risk of DM 
[241]. 
 Polyphenols are also beneficial to DM patients because 
of their capacity to improve insulin sensitivity [242, 243], to 
protect pancreatic β-cells against glucose toxicity, oxidative 
damage and cell apoptosis, to inhibit α-amylases or α-
glucosidases (consequently decreasing starch digestion), to 
inhibit advanced glycation products formation and to acti-
vate signaling pathways that improve glucose uptake in mus-
cle cells and adipocytes [25, 31]. Furthermore, polyphenols 
can also prevent the long-term development of complications 
associated with DM, such as cardiovascular disease, neu-
ropathy, nephropathy and retinopathy [25]. 
 On the other hand, the importance of developing new 
therapies for AD arises from the fact that currently pre-
scribed drugs are only able to reduce symptoms and improve 
cognitive decline but are not able to prevent or reverse the 
progression of the disease. It is thought that the lack of effi-
Polyphenols Action in Diabetes Mellitus and Alzheimer’s Disease Current Neuropharmacology, 2018, Vol. 16, No. 0    15 
cacy of these drugs is due to the majority being directed to-
wards only one mechanism, in the face of a multifactorial 
pathology that is characterized by complex relationships 
between several interconnected biological phenotypes [244]. 
AD involves various phenomena, such as the formation of 
amyloid and tau aggregates and cholinesterase disorders, and 
is exacerbated by oxidative stress, metal deposition, mito-
chondrial dysfunction, increased immune responses and 
mechanisms of chronic inflammation [26]. 
 Cohort studies in healthy older people showed that those 
with the highest polyphenol intakes had a significantly re-
duced risk of dementia [138] and that polyphenol-enriched 
diets improved cognition [245]. This is in agreement with 
Krikorian et al. [246], who showed that elderly individuals 
with mild cognitive decline demonstrated significantly im-
proved verbal learning after drinking grape juice for 12 
weeks. Thus, the ability of polyphenols to reduce oxidative 
stress and inflammation, modulate APP processing, prevent 
β-amyloid aggregation and favour disruption of preformed 
NFT, make them ideal for therapeutic use in AD [110]. 
 In this context, polyphenols are a possible alternative 
form of therapy capable of acting on several mechanisms 
inherent to the pathologies of DM and AD simultaneously. 
They also have the advantage of being compounds that are 
naturally found in the diet, so that their therapeutic imple-
mentation can be through a dietary alteration or nutritional 
supplements, which is more cost-effective, easier to imple-
ment, socially acceptable and generally safer [26]. 
5. LIMITATIONS AND PITFALLS 
 Despite the proven benefits of polyphenols, there are still 
limitations to be overcome prior to their implementation as 
therapeutic agents. The main limitation is the fact that the 
pharmacological action of polyphenols depends on their 
bioavailability in the organism. In the case of neurodegenera-
tive diseases, there is also the limiting factor that polyphe-
nols must be able to penetrate the blood-brain barrier, in a 
biologically active form and in a sufficient dose to exert neu-
roprotective effects, which might not be possible at the doses 
available in the diet or in supplements [247]. In addition, not 
all polyphenols can be absorbed, some are poorly absorbed 
from the gastrointestinal tract and rapidly eliminated from 
the body. Metabolic modification of polyphenols may further 
decrease their effect [247]. 
 In the case of DM, there is even evidence that the pathol-
ogy itself influences the benefits of polyphenols, causing 
changes in their pharmacokinetics and bioactivity. Therefore, 
it is necessary to understand these changes, in order to im-
prove the benefits of these phytochemicals and subsequent 
clinical outcomes for diabetic patients [31]. 
 Besides, consideration should also be given to possible 
interactions with other phytochemicals, food components or 
drugs that may decrease the beneficial effects of polyphenols 
or lead to toxicity [26]. Also, exaggerated consumption of 
certain compounds can lead to adverse effects, such as thy-
roid toxicity, malnutrition, estrogenic activity and infertility 
[247]. The studies performed on polyphenols influence are 
usually done during short periods of time, failing to ascertain 
the long-term effects, and there is no standard for the meth-
ods and models used in research. Therefore, both the mecha-
nism and the safety of administration of high doses of poly-
phenols need to be investigated, in order to verify if they 
actually act specific to certain pathologies, or whether they 
only stimulate normal healthy mechanisms [26]. 
 As future perspectives to overcome the current limita-
tions, new strategies, based on nanotechnology and new drug 
delivery systems, can be used to increase the bioavailability 
of the polyphenols and promote their penetration into the 
blood-brain barrier. For example, polyphenols may be en-
capsulated in phospholipid nanoparticles or incorporated in 
biodegradable polymers. There is also the possibility of us-
ing bioactive analogues to simulate polyphenols action or 
improve pharmacokinetics and use adjuvants to increase 
polyphenol uptake by the body. It is also fundamental to 
study more patients and use bigger samples during longer 
periods of time, in order to ascertain the effects of long-term 
treatment with polyphenols [248]. 
CONCLUSION 
 It is clear that a complex interplay between environ-
mental, nutritional and genetic factors plays a common role 
in DM and AD pathogenesis. Therefore, it is worthwhile to 
try dietary strategies that can counterattack these two pa-
thologies simultaneously. The polyphenols explored in this 
review can mitigate risk factors, progression and symptoms 
of DM and AD, as they are able to modulate carbohydrate 
and lipid metabolism, and they can penetrate the blood-brain 
barrier, having a neuroprotective effect, contributing to a 
healthier brain. However, it is not yet possible to fully ex-
plain the mechanisms involved in the therapeutic effects of 
polyphenols in DM and AD, as they are multifunctional 
agents, able to modulate several processes at the cellular and 
enzymatic levels and can have epigenetic effects. It is neces-
sary to continue studying polyphenols as potential nutraceu-
ticals and to solve the question of their bioavailability, at 
concentrations that allow pharmacological action, which is 
the major limiting challenge to their use as therapeutic 
agents [110]. 
LIST OF ABBREVIATIONS 
ACh = Acetylcholine 
AChE = Acetylcholinesterase 
AD = Alzheimer’s Disease 
ADP = Adenosine diphosphate 
Akt = Protein kinase b 
AMPK = 5' adenosine monophosphate-activated 
protein kinase 
ApoE = Apolipoprotein E 
APP = Amyloid precursor protein 
ATP = Adenosine triphosphate 
Bax = Bcl-2-like protein 4 
BChE = Butyrylcholinesterase 
Bcl-2 = B-cell lymphoma 2 
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CAT = Catalase 
DM = Diabetes Mellitus 
EC = Epicatechin 
ECG = Epicatechin gallate 
EGC = Epigallocatechin 
EGCG = Epigallocatechin-3-gallate 
ERK = Extracellular signal-regulated kinases 
FOXO = Forkhead box O 
G-6-Pase = glucose-6-phosphatase 
GLUT1 = Glucose transporter 1 
GLUT2 = Glucose transporter 2 
GLUT3 = Glucose transporter 3 
GLUT4 = Glucose transporter 4 
GSH = Glutathione 
GSH-Px = Glutathione peroxidase 
IGF-I = Insulin-like growth factor I 
IL-1 = Interleukin 1 
IL-6 = Interleukin 6 
LC–MS = Liquid chromatography-mass spectrometry 
LDH = Lactate dehydrogenase activity 
MAPK = Mitogen-activated protein kinases 
NAD = Nicotinamide adenine dinucleotide 
NADPH = Nicotinamide adenine dinucleotide phos-
phate 
NF-kB = Nuclear factor kappa-light-chain-
enhancer of activated B cells 
NFT = Neurofibrillary tangles 
PEPCK = Phosphoenolpyruvate carboxykinase 
PI3K = Phosphatidylinositol 3 kinase 
PGC-1α = Peroxisome proliferator-activated recep-
tor gamma coactivator 1-alpha 
PKC = Protein kinase C 
PS1 = Presenilin 1 
PSEN1 = Presenilin 1 gene 
ROS = Reactive oxygen species 
SIRT1 = Sirtuin 1 
SOD = Superoxide dismutase 
STZ = Streptozotocin 
T1DM = Type 1 diabetes mellitus 
T2DM = Type 2 diabetes mellitus 
TNF-α = Tumour Necrosis Factor alpha 
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